摘要
Pancreatic ductal adenocarcinoma(PDAC)is a disease with a particular aggressive cancer biology and,unfortunately,a very poor prognosis for most patients.There is no question about the lethality of pancreatic cancer.However,the question why this malignancy is so deadly remains a biological puzzle both to investigators and caretakers alike.Staging of pancreatic cancer undergoing resection-while important to compare cohorts across studies and trials-also allows for a clinical clue about the progress of the disease.
